Bharat Serum and Vaccine Limited (BSVL) have received approval from the Indian Pharmaceutical Regulator to test the pre-existing Ulinastatin

New Delhi: Bharat Serum and Vaccine Limited (BSVL) have received approval from the Indian Pharmaceutical Regulator to test the pre-existing Ulinastatin drug on 19 patients with severe Covid disease. This drug will be tested as a possible treatment for corona virus.

PhotoPrior to India Serums, Sun Pharmaceuticals Industries, Glenmark Pharmaceuticals and Strides Pharma Science have received approval for a human trial of a possible treatment for Covid-19.

BSVL said in a statement that its Indian Pharmaceutical Regulatory Commission (DCGI) has approved a third phase of Ulinastatin in Covid patients with mild to moderate respiratory illness, i.e. ARDS.

File PhotoUlinastatin is still approved in India for the treatment of chronic burns. Sanjiv Navangul, managing director and chief executive officer of the company, said that Ulinastatin would be used on critically ill patients who have been hospitalized due to ARDS. The human test will be performed in six to eight hospitals.